Medical Condition

metastatic malignant solid neoplasm

Total Trials

8

Recruiting Now

8

Trial Phases

Phase 1, Phase 2, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for metastatic malignant solid neoplasm sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — metastatic malignant solid neoplasm Clinical Trials

How many clinical trials are currently recruiting for metastatic malignant solid neoplasm?

ClinicalMetric currently tracks 8 actively recruiting clinical trials for metastatic malignant solid neoplasm, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 8. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for metastatic malignant solid neoplasm?

metastatic malignant solid neoplasm research spans Phase 1 (2 trials), Phase 2 (6 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a metastatic malignant solid neoplasm clinical trial?

Eligibility criteria for metastatic malignant solid neoplasm trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Top Sponsors

National Cancer Institute (NCI) 3 trials

Mayo Clinic 2 trials

M.D. Anderson Cancer Center 2 trials

University of Washington 1 trial

Recruiting Clinical Trials

NCT07137416 Phase 1

Recruiting

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

National Cancer Institute (NCI...

View Trial →

NCT05222620 Phase 2

Recruiting

SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

National Cancer Institute (NCI...

View Trial →

NCT05564377 Phase 2

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Enrollment

2,900 pts

Location

United States, Puert...

Sponsor

National Cancer Institute (NCI...

View Trial →

NCT05269381 Phase 1, Phase 2

Recruiting

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies

University of Washington

View Trial →

NCT05059678

Recruiting

Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis

M.D. Anderson Cancer Center

View Trial →

NCT04879121 Phase 2

Recruiting

Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

M.D. Anderson Cancer Center

View Trial →

Related Conditions

locally advanced malignant solid neoplasm (4) anatomic stage iii breast cancer ajcc v8 (3) anatomic stage iv breast cancer ajcc v8 (3) unresectable malignant solid neoplasm (3) metastatic triple negative breast carcinoma (2) unresectable triple negative breast carcinoma (2) recurrent malignant solid neoplasm (2) invasive breast carcinoma (1) locally advanced breast carcinoma (1) metastatic breast carcinoma (1) metastatic her2 low breast carcinoma (1) metastatic her2 positive breast carcinoma (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology